Palvella Therapeutics (PVLA) Cash & Equivalents: 2013-2024
Historic Cash & Equivalents for Palvella Therapeutics (PVLA) over the last 11 years, with Sep 2024 value amounting to $14.2 million.
- Palvella Therapeutics' Cash & Equivalents fell 68.29% to $14.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $14.2 million, marking a year-over-year decrease of 68.29%. This contributed to the annual value of $7.3 million for FY2023, which is 80.98% down from last year.
- Per Palvella Therapeutics' latest filing, its Cash & Equivalents stood at $14.2 million for Q3 2024, which was down 2.27% from $14.5 million recorded in Q2 2024.
- Over the past 5 years, Palvella Therapeutics' Cash & Equivalents peaked at $125.1 million during Q3 2021, and registered a low of $6.2 million during Q1 2024.
- Its 3-year average for Cash & Equivalents is $39.7 million, with a median of $44.8 million in 2023.
- In the last 5 years, Palvella Therapeutics' Cash & Equivalents soared by 168.83% in 2021 and then crashed by 87.09% in 2024.
- Palvella Therapeutics' Cash & Equivalents (Quarterly) stood at $70.4 million in 2020, then skyrocketed by 67.19% to $117.8 million in 2021, then tumbled by 67.19% to $38.6 million in 2022, then plummeted by 80.98% to $7.3 million in 2023, then crashed by 68.29% to $14.2 million in 2024.
- Its last three reported values are $14.2 million in Q3 2024, $14.5 million for Q2 2024, and $6.2 million during Q1 2024.